Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Trubion Pharmaceuticals, Inc (TRBN)
|
Add to portfolio |
|
|
|
| Price: |
$4.48
| | Metrics |
| OS: |
20.4
|
M
| |
|
|
| Market cap: |
$91.5
|
M
| |
|
|
|
Net cash:
|
$40.8
|
M
| |
$2.00
|
per share
|
|
EV:
|
$50.7
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 |
| Revenues | 34.4 | 31.6 | 36.5 | 33.3 | 0.3 | 0.3 | 3.4 |
| Revenue growth | 8.8% | -13.3% | 9.5% | 9444.1% | 18.7% | -91.4% | |
| Cost of goods sold | 46.8 | 43.0 | 47.3 | 42.8 | 19.4 | 14.5 | 5.7 |
| Gross profit | -12.4 | -11.4 | -10.8 | -9.5 | -19.0 | -14.2 | -2.3 |
| Gross margin | -36.1% | -36.0% | -29.7% | -28.4% | -5446.7% | -4828.9% | -67.4% |
| General and administrative | 12.4 | 11.4 | 10.8 | 9.5 | 4.1 | 2.9 | 2.3 |
| EBIT | -28.8 | -26.5 | -27.2 | -6.3 | -19.0 | -14.2 | -5.7 |
| EBIT margin | -83.8% | -83.9% | -74.5% | -18.8% | -5446.7% | -4828.9% | -167.4% |
| Pre-tax income | -29.2 | -25.6 | -23.3 | -3.9 | -18.9 | -14.2 | -5.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -29.2 | -25.6 | -23.3 | -3.9 | -18.9 | -14.2 | -5.6 |
| Net margin | -84.8% | -80.9% | -63.9% | -11.8% | -5423.2% | -4834.4% | -164.0% |
| |
| Diluted EPS | ($1.55) | ($1.43) | ($1.32) | ($0.83) | ($23.31) | ($22.45) | ($11.39) |
| Shares outstanding (diluted) | 18.8 | 17.9 | 17.7 | 4.7 | 0.8 | 0.6 | 0.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|